Publications by authors named "Andrew N J Tutt"

Claim this Profile

Mentions over time

Mentions by platform

Video Views

1,675,320

Total Likes

57,610

Extended Reach

2,210,393

Social Features

151
A
Adjuvant Olaparib for Patients with - or -Mutated Breast Cancer.
Andrew N J Tutt, Judy E Garber, Bella Kaufman, Giuseppe Viale, Debora Fumagalli, Priya Rastogi, Richard D Gelber, Evandro de Azambuja, Anitra Fielding, Judith Balmaña

June 2021

Videos about Article: user user user

3 5 148 8 92

View All Article and Social Media Activity
A
An Fc-Engineered Glycomodified Antibody Supports Proinflammatory Activation of Immune Effector Cells and Restricts Progression of Breast Cancer.
Alicia M Chenoweth, Anthony Cheung, Jitesh Chauhan, Rebecca Adams, Gabriel Osborn, Andrew N J Tutt

Cancer Res· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NASP modulates histone turnover to drive PARP inhibitor resistance.
Sarah C Moser, Anna Khalizieva, Josef Roehsner, Elisabeth Pottendorfer, Milo L Kaptein, Andrew N J Tutt

Nature· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PPP2R1A mutations cause ATR inhibitor sensitivity in ovarian clear cell carcinoma.
James Stewart, Dragomir B Krastev, Rachel Brough, Diana Zatreanu, Feifei Song, Andrew N J Tutt

Oncogene· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The transcriptomic architecture of common cancers reflects synthetic lethal interactions.
Syed Haider, Rachel Brough, Santiago Madera, Jacopo Iacovacci, Aditi Gulati, Andrew N J Tutt

Nat Genet· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Proteogenomic discovery of -defective phenocopy in cancer predicts disease outcome, response to treatment, and therapeutic targets.
Jacopo Iacovacci, Rachel Brough, Fatemeh Ahmadi Moughari, John Alexander, Harriet Kemp, Andrew N J Tutt

Sci Adv· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-EGFR Antibody-Drug Conjugate Carrying an Inhibitor Targeting CDK Restricts Triple-Negative Breast Cancer Growth.
Anthony Cheung, Alicia M Chenoweth, Annelie Johansson, Roman Laddach, Naomi Guppy, Andrew N J Tutt

Clin Cancer Res· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient-Reported Outcomes in OlympiA: A Phase III, Randomized, Placebo-Controlled Trial of Adjuvant Olaparib in g Mutations and High-Risk Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer.
Patricia A Ganz, Hanna Bandos, Tanja Španić, Sue Friedman, Volkmar Müller, Andrew N J Tutt

J Clin Oncol· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cancer-associated FBXW7 loss is synthetic lethal with pharmacological targeting of CDC7.
Joseph S Baxter, Rachel Brough, Dragomir B Krastev, Feifei Song, Sandhya Sridhar, Andrew N J Tutt

Mol Oncol· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genomic profiling and pre-clinical modelling of breast cancer leptomeningeal metastasis reveals acquisition of a lobular-like phenotype.
Amanda Fitzpatrick, Marjan Iravani, Adam Mills, David Vicente, Thanussuyah Alaguthurai, Andrew N J Tutt

Nat Commun· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A HUWE1 defect causes PARP inhibitor resistance by modulating the BRCA1-∆11q splice variant.
Stephen J Pettitt, Nan Shao, Diana Zatreanu, Jessica Frankum, Ilirjana Bajrami, Andrew N J Tutt

Oncogene· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MND1 and PSMC3IP control PARP inhibitor sensitivity in mitotic cells.
Anabel Zelceski, Paola Francica, Lea Lingg, Merve Mutlu, Colin Stok, Andrew N J Tutt

Cell Rep· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Systemic Therapy for Hereditary Breast Cancers.
Elizabeth J Harvey-Jones, Christopher J Lord, Andrew N J Tutt

Hematol Oncol Clin North Am· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Opinion: PARP inhibitors in cancer-what do we still need to know?
Andrew J Wicks, Dragomir B Krastev, Stephen J Pettitt, Andrew N J Tutt, Christopher J Lord

Open Biol· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessing CSF ctDNA to Improve Diagnostic Accuracy and Therapeutic Monitoring in Breast Cancer Leptomeningeal Metastasis.
Amanda Fitzpatrick, Marjan Iravani, Adam Mills, Lucy Childs, Thanussuyah Alaguthurai, Andrew N J Tutt

Clin Cancer Res· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The ubiquitin-dependent ATPase p97 removes cytotoxic trapped PARP1 from chromatin.
Dragomir B Krastev, Shudong Li, Yilun Sun, Andrew J Wicks, Gwendoline Hoslett, Andrew N J Tutt

Nat Cell Biol· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TGF-β1 potentiates Vγ9Vδ2 T cell adoptive immunotherapy of cancer.
Richard E Beatson, Ana C Parente-Pereira, Leena Halim, Domenico Cozzetto, Caroline Hull, Andrew N J Tutt

Cell Rep Med· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sirtuin inhibition is synthetic lethal with BRCA1 or BRCA2 deficiency.
Ilirjana Bajrami, Callum Walker, Dragomir B Krastev, Daniel Weekes, Feifei Song, Andrew N J Tutt

Commun Biol· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adjuvant Olaparib in BRCA-Mutated Breast Cancer. Reply.
Andrew N J Tutt, Judy E Garber, Charles E Geyer

N Engl J Med· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumor-Infiltrating B Lymphocyte Profiling Identifies IgG-Biased, Clonally Expanded Prognostic Phenotypes in Triple-Negative Breast Cancer.
Robert J Harris, Anthony Cheung, Joseph C F Ng, Roman Laddach, Alicia M Chenoweth, Andrew N J Tutt

Cancer Res· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Reversion Analysis Identifies Hotspot Mutations and Predicted Neoantigens Associated with Therapy Resistance.
Stephen J Pettitt, Jessica R Frankum, Marco Punta, Stefano Lise, John Alexander, Andrew N J Tutt

Cancer Discov· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
AllergoOncology: Expression platform development and functional profiling of an anti-HER2 IgE antibody.
Kristina M Ilieva, Judit Fazekas-Singer, Heather J Bax, Silvia Crescioli, Laura Montero-Morales, Andrew N J Tutt

Allergy· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Four-gene Decision Tree Signature Classification of Triple-negative Breast Cancer: Implications for Targeted Therapeutics.
Jelmar Quist, Hasan Mirza, Maggie C U Cheang, Melinda L Telli, Joyce A O'Shaughnessy, Andrew N J Tutt

Mol Cancer Ther· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-Folate Receptor Alpha-Directed Antibody Therapies Restrict the Growth of Triple-negative Breast Cancer.
Anthony Cheung, James Opzoomer, Kristina M Ilieva, Patrycja Gazinska, Ricarda M Hoffmann, Andrew N J Tutt

Clin Cancer Res· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis